Friday 6 November 2026 Export CAI’s income statement to Excel — free account

Caris Life Sciences,�Inc.

Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.

Revenue: +27.0%
EPS: −40.3%
Free cash flow: −140.2%
Total debt: +4.46%

Quarter to September 2026, against a year earlier

Insider buying

25.52 0.51 −1.96%

Follow CAI

Alert me

Market cap: $7.4B
P/E: 77.7×
Fwd P/E: 254×
Dividend yield: —
F-score: n/a
Altman Z: 3.55
Beneish M: −2.71
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Caris Life Sciences,�Inc. (CAI) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Caris Life Sciences,�Inc. (CAI) trades at a P/B ratio of 12.7×. Over the past ten years it has ranged from 0.0× (June 2025) to 19.4× (October 2025); the current reading is higher than 66% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/CAI/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Caris Life Sciences,�Inc. P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/CAI/metrics/pb-ratio">Caris Life Sciences,�Inc. (CAI) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	13.2×	—
FY2024	0.0×	—
FY2023	0.0×	—

Period	P/B ratio	Change
Sep 2026	14.7×	72.50%
Jun 2026	8.5×	0.08%
Mar 2026	8.5×	(35.46%)
Dec 2025	13.2×	(26.07%)
5 more quarters	Free account

Against its own ten years

Low 0.0× High 19.4×

Ten-year median 9.5×

Current reading's percentile 66

Company	P/B ratio
CYTK Cytokinetics, Incorporated compare	n/m
IBRX ImmunityBio, Inc. compare	n/m
KRYS Krystal Biotech, Inc. compare	6.2×
SYRE Spyre Therapeutics, Inc. compare	9.5×
PTGX Protagonist Therapeutics, Inc. compare	10.6×
CAI Caris Life Sciences,�Inc.	12.7×
TGTX TG Therapeutics, Inc. compare	13.6×
TWST Twist Bioscience Corporation compare	17.1×
MDGL Madrigal Pharmaceuticals, Inc. compare	18.7×
Biotechnology industry median	2.0×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Caris Life Sciences,�Inc. (CAI) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on CAI

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on CAI

Stockrow Weekly